Healthcare company Avrio Health LP said on Thursday that the Betadine Antiseptic Sore Throat Gargle (active ingredient, povidone-iodine or PVP-I) killed 99.9% of the COVID-19 virus within 15 seconds in an in vitro (laboratory) study.
The company added that the Betadine Gargle containing 0.5% PVP-I demonstrated virucidal activity against SARS-CoV-2 and four surrogate coronaviruses in separate in vitro studies conducted by Utah State University, Institute for Antiviral Research, BluTest Laboratories, Tropical Infectious Diseases Research and Education Center at the University of Malaya, Malaysia as well as the Duke-NUS Medical School in Singapore.
According to the company, Betadine Antiseptic Sore Throat Gargle (0.5% povidone-iodine antiseptic gargle), which should not be swallowed, is an oral antiseptic with use for the temporary relief of occasional sore throat. Betadine Antiseptic Sore Throat Gargle will be available in retail stores in late August 2020. All products should be used only as directed on the label.
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial